Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)

Recurrent Skin Cancer Clinical Trial

Official title:

A Pilot Study to Investigate the Off Label Use of Vismodegib as an Adjuvant to Surgery for Basal Cell Carcinoma Tumors (BCCs)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01631331
• Other study ID #: IRB-24313
• Secondary ID: NCI-2012-01055SK
• Status: Completed
• Phase: Early Phase 1
• First received: June 25, 2012
• Last updated: November 6, 2017
• Start date: June 2012
• Est. completion date: May 31, 2016

Study information

• Verified date: August 2017
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to learn about the effect of vismodegib on sporadic basal cell carcinoma (BCCs) prior to surgical removal.

Description:

PRIMARY OBJECTIVES:

I. The percent reduction in surgical defect area/size surrounding BCC tumor pre and post-vismodegib.

SECONDARY OBJECTIVES:

I. Recurrence rate post treatment II. Safety, tolerability and percent drop-out after 3 vs. 6 months of vismodegib in otherwise healthy patients.

OUTLINE:

Patients receive vismodegib orally (PO) once daily (QD) for up to 3 months if the initial BCC size is < 2 cm and superficial or for up to 6 months if the initial BCC size is >= 2 cm or non-superficial. After completion of vismodegib treatment, patients undergo Mohs surgery.

After completion of study treatment, patients are followed up for an average of 24 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: May 31, 2016
• Est. primary completion date: September 17, 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Study patients must have at least one BCC, > 5 mm, eligible for Mohs surgical removal; patients with BCCs that have been treated before (recurrent BCCs, BCCs that failed other chemotherapy) are eligible for this trial, if they meet size criteria

• No Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance status will be employed

• Normal hepatic function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x the upper limit of normal (ULN)

• Normal renal function : normal serum creatinine defined as <= 2.5 mg/dL

• Clinically acceptable complete blood count (CBC)

• Ability to understand and the willingness to sign a written informed consent document

• The patient is willing to forego surgical treatment of BCCs by up to 6 months, except when the principal investigator (PI) believes that delay in treatment potentially might compromise the health of the subject

• Documented negative serum pregnancy test for women of childbearing potential, with agreement to the use of two acceptable methods of contraception during the study and for 7 months after discontinuation of vismodegib

• For men with female partners of childbearing potential, agreement to use a latex, non-latex, or any other male condom and to advise their female partners to use an additional acceptable method of birth control during the study and for 2 months after discontinuation of study drug

• Be willing to not donate blood or semen for three months following discontinuation of study medications

Exclusion Criteria:

• The patient has a history of invasive cancer within the past five years excluding non-melanoma skin cancer, stage I cervical cancer, ductal carcinoma in situ of the breast, or chronic lymphocytic leukemia (CLL) stage 0

• The subject has uncontrolled systemic disease, including known human immunodeficiency virus (HIV) positive patients:

• The patient has history of congestive heart failure

• The patient has clinically important history of liver disease, including viral or hepatitis, current alcohol abuse, or cirrhosis

• The patient has any condition or situation which in the investigator's opinion may put the patient at significant risk, could confound the study results, or could interfere significantly with the subject's participation in the study; this includes history of other skin conditions or disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the patient at high risk from treatment complications

• The patient has a history of hypersensitivity to any of the ingredients in the study medication formulations

• The patient is willing to abstain from application of non-study topical medications to the skin for the duration of the study, including prescription and over the counter preparations; for example, topical preparations containing corticosteroids or vitamin A derivatives are not allowed

• Pregnant or nursing patients will be excluded from the study

Related Conditions & MeSH terms

• Basal Cell Carcinoma of the Skin
• Carcinoma
• Carcinoma, Basal Cell
• Recurrent Skin Cancer
• Skin Neoplasms

Intervention

Drug:
• vismodegib
Given PO

Procedure:
• Mohs surgery
Undergo Mohs surgery

Locations

Country	Name	City	State
United States	Stanford University	Stanford	California

Sponsors (3)

Lead Sponsor	Collaborator
Stanford University	National Cancer Institute (NCI), University Hospitals Cleveland Medical Center

Country where clinical trial is conducted

United States, 

References & Publications (1)

Ally MS, Aasi S, Wysong A, Teng C, Anderson E, Bailey-Healy I, Oro A, Kim J, Chang AL, Tang JY. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol. 2014 Nov; — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent Change in Surgical Defect Area After the Treatment Period Using Calipers and Photographs Was Calculated	At baseline, we selected 1 to 2 tumors per patient for surgery (13 target tumors selected). At baseline,1 Mohs surgeon measured the estimated surgical defect area around the target tumor. For tumors to be excised by Mohs we defined estimated surgical defect as the tumor size plus a 2-mm circumferential margin, presuming tumor clearance after a Mohs stage-1 excision. For the tumor undergoing standard (non-Mohs) excision, we used tumor size plus a standard 4-mm margin11 for the estimated surgical defect. On the day of the surgery, we measured the surgical defect area as the final tumor-free defect after the Mohs procedure or non-Mohs excision immediately before closure. We used the Image J software program (National Institutes of Health, Bethesda, MD) to calculate tumor area (cm2). Only target tumors are included in this analysis.	average of 4 months
Secondary	Number of Tumors Demonstrating Histologic Cure	Determination of histologic cure (no residual BCC on the ?rst piece of excised tissue) post serial sectioning of paraf?n embedded Mohs specimens	Average of 4 months
Secondary	Tumor Recurrence Rate of Treated BCCs	Recurrence rate of BCCs during a 22 month average (range 12 to 28 months) follow up period.	average of 22 months
Secondary	Tumor Size Measurements Before and After Short Term Vismodegib Treatment	We measured the length and width of all tumors (target and non-target) before and after vismodegib treatment.	4 months (average)